Seminars in Nuclear Medicine
Volume 32, Issue 3 , Pages 159-172 , July 2002

The natural history of venous thromboembolism: Impact on ventilation/perfusion scan reporting

  • Henry W. Gray

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Henry W. Gray, MD, FRCP, Department of Nuclear Medicine, The Royal Infirmary, Alexandra Parade, Glasgow, G4 0SF, Scotland.

References 

  1. Sevitt S, Gallagher N. Venous thrombosis and pulmonary embolism. A clinico-pathological study in injured and burned patients. Br J Surg. 1961;48:475–489
  2. Line BR. Pathophysiology and diagnosis of deep vein thrombosis. In: Semin Nucl Med. 31:2002;p. 90–101
  3. Elliot G. Pulmonary physiology during pulmonary embolism. Chest. 1992;101:163S–171S
  4. Moser KM. Venous thromboembolism. Am Rev Respir Dis. 1990;141:235–249
  5. Moser KM, Fedulla PF, Littlejohn JK, et al. Frequent asymptomatic pulmonary embolism in patients with deep vein thrombosis. JAMA. 1994;271:223–225
  6. Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation lung scanning and venography for clinically suspected pulmonary embolism with abnormal perfusion scan. Ann Intern Med. 1983;98:891–899
  7. Huisman MV, Buller HR, ten Cate JW, et al. Unexpected high prevalence of silent PE in patients with deep vein thrombosis. Chest. 1995;95:498–502
  8. Meignan M, Rosso J, Gauthier H, et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep vein thrombosis. Arch Intern Med. 2000;160:159–164
  9. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis. J R Soc Med. 1989;82:203–205
  10. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975;17:259–270
  11. Prandoni P, ten Cate JW. Epidemiology, risk factors and natural history of venous thromboembolism. In: Oudkerk M, van Beek EJR, ten Cate JW editor. Pulmonary Embolism: Epidemiology, Diagnosis and Treatment. Boston, MA: Blackwell Science; 1999;p. 2–32
  12. Lilienfield DE, Chan E, Ehland J, et al. Mortality from pulmonary embolism in the United States, 1962 to 1984. Chest. 1990;98:1067–1072
  13. Rossman I. True incidence of pulmonary embolisation and vital statistics. JAMA. 1974;230:1677–1679
  14. Morrell MT, Truelove SC, Barr A. Pulmonary embolism. BMJ. 1963;2:830–835
  15. Lilienfield DE, Godbold JH, Burke GL, et al. Hospitalisation and case fatality for pulmonary embolism in the twin cities: 1979–1984. Am Heart J. 1990;120:392–395
  16. Morrell MT, Dunhill MS. The post-mortem incidence of pulmonary embolism in a hospital population. Br J Surg. 1968;55:347–352
  17. Dismuke SE, Wagner EH. Pulmonary embolism as a cause of death. The changing mortality in hospitalised patients. JAMA. 1986;255:2039–2042
  18. Freiman DG, Suyemoto J, Wessler S. Frequency of pulmonary thromboembolism in man. N Engl J Med. 1965;272:1278–1280
  19. Goldhaber SZ, Savage DD, Garrison RJ, et al. Risk factors for pulmonary embolism. The Framingham study. Am J Med. 1983;74:1023–1028
  20. Svendson E, Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol. 1989;42:805–809
  21. Karwinski B, Svendson E. Comparison of clinical and post-mortem diagnosis of pulmonary embolism. J Clin Pathol. 1989;42:135–139
  22. Clarke-Pearson DL, Jelovsek FR, Creasman WT. Thromboembolism complicating surgery for cervical and uterine malignancy: Incidence, risk factors and prophylaxis. Obstet Gynecol. 1983;61:87–94
  23. Scurr JH, Coleridge-Smith PD, Hasty JH. Deep vein thrombosis: A continuing problem. BMJ. 1988;297:28
  24. Huber O, Bounameaux H, Borst F, et al. Post-operative pulmonary embolus after hospital discharge. An underestimated risk. Arch Surg. 1992;127:310–313
  25. Gjores JE. The incidence of venous thrombosis and its sequelae in certain districts of Sweden. Acta Chir Scand Suppl. 1956;206:1–88
  26. Coon WW, Willis PW, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation. 1973;48:839–846
  27. Kierkegaard A. Incidence of acute deep venous thrombosis in two districts. A phlebographic study. Acta Chir Scand. 1980;146:267–269
  28. Anderson FA, Brownell-Wheeler H, Goldberg RJ, et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med. 1991;151:933–938
  29. Buck JR, Connors RH, Coon WW, et al. Pulmonary embolism in children. J Pediatr Surg. 1981;16:385–391
  30. Bernstein D, Coupey S, Schonberg SK, et al. Pulmonary embolism in adolescents. Am J Dis Child. 1986;140:667–671
  31. Massicote MP, Dix D, Monagle P, et al. Central venous catheter related thrombosis in children: Analysis of the Canadian registry of venous thromboembolism complications. J Pediatr. 1998;133:770–776
  32. Oger E. Incidence of venous thromboembolism. A community-based study in Western France. Thromb Haemost. 2000;83:657–660
  33. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452–463
  34. Melton LJ. History of the Rochester epidemiology project. Mayo Clin Proc. 1996;71:266–274
  35. Kurland LT, Molgaard CA. The patient record in epidemiology. Sci Am. 1981;245:54–63
  36. Bratzler DW, Rascob GE, Murray CK, et al. Underuse of venous thromboembolism prophylaxis for general surgery patients. Arch Intern Med. 1998;158:1909–1912
  37. Lowe GDO, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol. 1997;97:775–784
  38. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost. 1999;82:610–619
  39. Carson JH, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326:1240–1245
  40. Van Beek EJR, Kuijer PMM, Buller HR, et al. The clinical course of patients with suspected pulmonary embolism. Arch Intern Med. 1997;157:2593–2598
  41. Alpert JS, Smith R, Carlson J. Mortality in patients treated for pulmonary embolism. JAMA. 1976;236:1477–1480
  42. Kniffin WD, Baron JA, Barrett J, et al. The epidemiology of diagnosed pulmonary embolism and deep vein thrombosis in the elderly. Arch Intern Med. 1994;154:861–866
  43. Gillum RF. Pulmonary embolism and thrombophlebitis in the United States, 1970–1985. Am Heart J. 1987;114:1262–1264
  44. Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279:458–462
  45. Nemetz PN, Ballard DJ, Beard CM, et al. An anatomy of the autopsy, Olmsted county, 1935 through 1985. Mayo Clin Proc. 1989;64:1055–1064
  46. Virchow R. Die Verstoptung der Lungenarterie und ihre Folgen. Beitr Z Exper Path Phys. 1846;2:1
  47. Virchow R. Neuer Fall von todlcher Embolie der Lungenarterien. Arch F Patholog Anat U Phys. 1856;10:225
  48. McColl MD, Tait RC, Greer IA, et al. Injecting drug use is a risk factor for deep vein thrombosis in women in Glasgow. Br J Haematol. 2001;112:641–643
  49. Egeburg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516–530
  50. Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981;68:1370–1373
  51. Schwartz HP, Fischer M, Hopmeier P, et al. Plasma protein S deficiency in familial thrombotic disease. Blood. 1984;64:1297–1300
  52. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C: Prediction of a co-factor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004–1008
  53. Bucciarelli P, Rosendaal FR, Tripodi A, et al. Risk of venous thromboembolism and clinical manifestations of carriers of antithrombin, protein C, protein S deficiency or activated protein C resistance. A multicentre collaborative family study. Arterioscler Thromb Vasc Biol. 1999;19:1026–1033
  54. Allaart CF, Poort SR, Rosendaal FR, et al. Increased risk of venous thrombosis in carriers of hereditary protein C defect. Lancet. 1993;341:134–138
  55. Gladson CL, Scharrer I, Hach V, et al. The frequency of type 1 heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost. 1988;59:18–22
  56. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517–522
  57. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet. 1993;342:1503–1506
  58. Bertina RM, Koelman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–67
  59. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–3703
  60. Koster T, Blaun AD, Briet E, et al. Role of clotting factor VIII in effect of von Williebrand factor on occurrence of deep vein thrombosis. Lancet. 1995;345:152–155
  61. den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: A meta-analysis. Thromb Haemost. 1998;80:874–877
  62. Meijers JCM, Tekelenburg WLH, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342:696–701
  63. Lowe GDO. Factor IX and thrombosis. Br J Haematol. 2001;115:507–513
  64. Rosendaal FR. Venous thrombosis: A multicausal disease. Lancet. 1993;353:1167–1173
  65. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost. 1999;82:610–619
  66. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 1994;87:106–112
  67. Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C in the healthy population. Thromb Haemost. 1995;73:87–93
  68. Lensen RPM, Rosendaal FR, Koster T, et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood. 1996;88:4205–4208
  69. Branson HE, Marble R, Katz J, et al. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn. Lancet. 1983;2:1165–1168
  70. Mahasanda C, Suvatte V, Chuansumrit A, et al. Homozygous protein S deficiency in an infant with purpura fulminans. J Pediatr. 1990;117:750–753
  71. New York Lane DA, Olds RF, Thein SL. Antithrombin and its Deficiency. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD editor. Haemostasis and thrombosis. Vol. 1:1994;p. 655–670
  72. Greer IA. Thrombosis in pregnancy: Maternal and fetal issues. Lancet. 1999;353:1258–1265
  73. McColl MD, Ramsey JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;78:1183–1188
  74. Bokarewa MI, Bremme K, Blomback M. Arg 506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol. 1996;92:473–478
  75. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340:9–13
  76. Koster T, Small RA, Rosendaal FR, et al. Oral contraceptives and venous thromboembolism: A quantitative discussion of the uncertainties. J Intern Med. 1995;238:31–37
  77. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with different progestagen components. Lancet. 1995;346:1589–1593
  78. Chasan-Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med. 1998;128:467–477
  79. Rosing J, Tans G, Nicolaes AF, et al. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 1997;97:233–238
  80. Vandenbrouke JP, Koster T, Briet E, et al. Increased risk of venous thromboembolism in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453–1457
  81. Daly E, Vessy MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977–980
  82. Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of post-menopausal oestrogens. Lancet. 1996;348:981–983
  83. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348:983–987
  84. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, et al. Hormone replacement therapy and the risk of hospitalisation for venous thromboembolism: A population-based study of Southern Europe. Am J Epidemiol. 1998;147:387–390
  85. Grady D, Sawaya G. Postmenopausal hormone therapy increases risk of deep vein thrombosis and pulmonary embolism. Am J Med. 1998;105:41–43
  86. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189–2197
  87. Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med. 1994;154:164–168
  88. Donati BM. Cancer and thrombosis: From phlegmasia alba dolens to transgenic mice. Thromb Haemost. 1995;74:278–281
  89. Prandoni P, Lensing AWA, Buller HR, et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128–1133malignant disease. In: Prandoni P editors. The Diagnostic and Therapeutic Managment of Deep Vein Thrombosis and Its Sequelae. Dissertation. University of Amsterdam; 1992;
  90. Love PE, Antoro SE. Antiphospholipid antibodies: Anticardiolipin antibodies and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med. 1990;112:682–698
  91. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet. 1999;353:1348–1353
  92. Schulman S, Svenungsson E, Granquist S, et al. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med. 1998;104:332–338
  93. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;86:3685–3691
  94. Gibbs NM. Venous thrombosis of the lower limb with particular reference to bedrest. Br J Surg. 1957;45:209–235
  95. Carter CJ. The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis. 1994;36:423–438
  96. Heit JA, Silverstein MD, Mohr D, et al. Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2000;160:809–815
  97. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998;158:1525–1531
  98. Simpson K. Shelter deaths from pulmonary embolism. Lancet. 1940;2:744
  99. Homans J. Thrombosis of the deep leg veins due to prolonged sitting. N Engl J Med. 1954;250:148–149
  100. Cruikshank JM, Gorlin R, Jennett B. Air travel and thrombotic episodes: The economy class syndrome. Lancet. 1988;2:497–498
  101. Mercer A, Brown J. Venous thromboembolism associated with air travel: A report of 33 patients. Aviat Space Environ Med. 1998;69:154–157
  102. Arfvidsson B, Eklof B, Kistner RL, et al. Risk factors for venous thromboembolism following prolonged air travel: A prospective study. Vasc Surg. 1999;33:537–544
  103. Burnand KG, Smith A. Air travel and deep vein thrombosis—The London experience. Cardiovasc Surg. 2001;9:146–147
  104. Lapostolle F, Surget V, Borron SW, et al. Severe pulmonary embolism associated with air travel. N Engl J Med. 2001;345:779–783
  105. Levy Y, George J, Shoenfield Y. The occurrence of thromboembolic events following airplane flights—The economy class syndrome. Isr J Med Sci. 1995;31:621–623
  106. Drysdale HC. Flight and risk of venous thrombosis. Aviat Space Environ Med. 1995;66:283
  107. Kraaijenhagen RA, Haverkamp D, Koopman MMW, et al. Travel and risk of venous thrombosis. Lancet. 2000;356:1492–1493
  108. Ferrari E, Morgan G. Travel and risk of venous thrombosis. Lancet. 2001;357:553
  109. Reele SB. Travel and risk of venous thrombosis. Lancet. 2001;357:553
  110. Burnand K, Waltham M, Smith A. Travel and risk of venous thrombosis. Lancet. 2001;357:554
  111. Cates C. Travel and risk of venous thrombosis. Lancet. 2001;357:553
  112. Gallus AS, Baker RI. Economy class syndrome. A misnomer for a syndrome for which the evidence is, as yet, missing. Med J Australia. 2001;174:264–265
  113. Ansell JE. Air travel and venous thromboembolism—Is the evidence in?. N Engl J Med. 2001;345:828–829
  114. Ferrari E, Chevalier T, Chapelier A, et al. Travel as a risk factor for venous thromboembolic disease. A case control study. Chest. 1999;115:440–444
  115. Emondson DL. Activated protein C resistance as a ‘new’ cause of deep vein thrombosis in aviators. Aviat Space Environ Med. 1997;68:606–608
  116. Eekhoff EMW, Roendaal FR, Vandenbrouke JP. Minor events and the risk of deep vein thrombosis. Thromb Haemost. 2000;83:408–411
  117. Schambeck C, Schwender S, Haubitz I, et al. Selective screening for the Factor V Leiden mutation. Is it advisable prior to the prescription of oral contraceptives?. Thromb Haemost. 1997;78:1480–1483
  118. Rosendaal FR. Venous thrombosis: A multicausal disease. Lancet. 1993;353:1167–1173
  119. Freeman LM, Krynycky B, Zuckier LS. Enhanced lung scan diagnosis of pulmonary embolism with the use of ancillary scintigraphic findings and clinical correlation. Semin Nucl Med. 2001;31:143–157
  120. Torbick A, van Beek EJR, Charbonnier B, et al. Guidelines on diagnosis and managment of acute pulmonary embolism. Eur Heart J. 2000;21:1301–1336
  121. Gray HW, Bessent RG. Pulmonary embolism exclusion: A practical approach to low probability using the PIOPED data. Eur J Nucl Med. 1998;25:271–276
  122. Gray HW, Bessent RG, McKillop JH. A preliminary evaluation of diagnostic odds in lung scan reporting. Nucl Med Commun. 1998;19:113–118
  123. Gray HW, Neilly JB. The role and value of ventilation perfusion imaging in pulmonary embolism. In: Oudkerk M, van Beek EJR, ten Cate JW editor. Pulmonary Embolism: Epidemiology, Diagnosis and Treatment. Boston, MA: Blackwell Science; 1999;p. 84–123
  124. Gottschalk A, Juni JE, Sostman HD, et al. Ventilation-perfusion scintigraphy in the PIOPED study. Part 2. Evaluation of the scintigraphic criteria and interpretation. J Nucl Med. 1993;34:1119–1126
  125. Gray HW. The languages of lung scan interpretation. In: Freeman LM editors. Nuclear Medicine Annual 2001. Philadelphia, PA: Lippincott Williams and Wilkins; 2001;p. 23–47
  126. Perrier A, Miron MJ, Desmarais S, et al. Using clinical evaluation and lung scan to rule out suspected pulmonary embolism. Arch Intern Med. 2000;160:512–516
  127. Miniati M, Pistolesi M, Marini C, et al. Value of perfusion lung scan in the diagnosis of pulmonary embolism: Results of the prospective investigative study of acute pulmonary embolism diagnosis (PISA-PED). Am J Respir Crit Care Med. 1996;154:1387–1393
  128. Hoellerich VL, Wigton RS. Diagnosing pulmonary embolism using clinical findings. Arch Intern Med. 1986;146:1699–1704
  129. Celia A, Palla A, Petruzzelli S, et al. Prospective study of a standardised questionnaire to improve clinical estimate of pulmonary embolism. Chest. 1989;95:332–337
  130. Perrier A, Bounameaux H. Cost-effective diagnosis of deep vein thrombosis and pulmonary embolism. Thromb Haemost. 2001;86:475–487
  131. Wells PS, Ginsberg JS, Anderson DR, et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med. 1998;129:997–1005
  132. Morabia A, Steinig-Stamm M, Unger PF, et al. Application of decision analysis to every-day clinical work: A controlled feasibility trial. J Gen Intern Med. 1994;9:496–502
  133. Wicki J, Perneger TV, Junod A, et al. Assessing clinical probability of pulmonary embolism in the emergency ward: A simple score. Arch Intern Med. 2001;161:92–97
  134. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: Increasing the model's utility with the simpliRED D-dimer. Thromb Haemost. 2000;83:416–420
  135. Neilly JB, Davidson J, McCarter D, et al. CT pulmonary angiography in patients with suspected acute pulmonary embolism [abstract]. Nucl Med Commun. 2000;21:392

PII: S0001-2998(02)80002-2

doi: 10.1053/snuc.2002.124176

Seminars in Nuclear Medicine
Volume 32, Issue 3 , Pages 159-172 , July 2002

Article Tools